Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD placebo-controlled study of RGH-338 in healthy male volunteers
NL-OMON55280Active, not recruiting
- Sponsor
- Gedeon Richter Plc
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing RGH-338 with Placebo (2 arms). Started Mar 2020; status: active, not recruiting.
02
Drugs
RGH-338
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON55280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55280.